Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposes Illuminating OTC Monograph Process With Sunscreen TEA Framework

This article was originally published in The Tan Sheet

Executive Summary

A proposed rule that sets deadlines for multiple steps in its reviews of TEAs for OTC ingredients should make the monograph process more transparent to the industry, but a timeline for sunscreen ingredient TEAs, as required by the Sunscreen Innovation Act, has not opened a door on application approvals.

You may also be interested in...



OTC Monograph Application Reviews Get Deadlines, Not GRASE Flexibility

Changes to FDA's interpretation of the GRASE standard it uses to evaluate ingredient proposals would go further to opening the US monograph process to innovation and progress than setting deadlines for the reviews, industry stakeholders say.

OTC Monograph Application Reviews Get Deadlines, Not GRASE Flexibility

Changes to FDA's interpretation of the GRASE standard it uses to evaluate ingredient proposals would go further to opening the US monograph process to innovation and progress than setting deadlines for the reviews, industry stakeholders say.

OTC Monograph User Fees: FDA-Industry Talks Move From Basics To Details

CDER officials and industry met in July to discuss "the ground rules governing the OTC monograph user fee." CHPA CEO Scott Melville cautions: "No one is going to rush into an agreement that we're going to have to live with for decades."

Related Content

Topics

UsernamePublicRestriction

Register

ID1132046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel